A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)
I6T-MC-AMAJ - ClinicalTrials.gov - NCT03535194
The reason for this study is to see how effective and safe mirikizumab is compared to secukinumab and placebo for moderate to severe plaque psoriasis.
Trial Summary
Age Range
≥18 yearsConditions the trial is for
PsoriasisWhat the trial is testing?
Mirikizumab, SecukinumabCould I receive a Placebo?
YesEnrollment Goal
1484Trial Dates
Jun 26, 2018 - Jun 3, 2020How long will I be in the trial?
The study will last about 56 weeks with 12 week follow-up and may include up to 20 visits.Trial Phase
IIIKey Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participant must have chronic plaque psoriasis for at least 6 months
Participants Must Not:
Participant must not be breastfeeding or nursing
Participant must not have had serious or chronic/recurring infection within 3 months
Participant must not have any other skin conditions (excluding psoriasis)
Participant must not have previous exposure to Cosentyx, Taltz, Stelara, or similar medications
Lilly Trial Alerts
Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
You will complete the questionnaire on another website.YesNo